Tower Research Capital LLC (Trc) Vaxcyte, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,992 shares of PCVX stock, worth $289,653. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,992
Previous 9,306
35.61%
Holding current value
$289,653
Previous $302,000
28.81%
% of portfolio
0.01%
Previous 0.01%
Shares
21 transactions
Others Institutions Holding PCVX
# of Institutions
322Shares Held
134MCall Options Held
408KPut Options Held
116K-
Janus Henderson Group PLC London, X013.1MShares$633 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$596 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$578 Million7.4% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$480 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.32MShares$402 Million0.18% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.87B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...